



PDA Standard 02-2021

**Cryopreservation of Cells for Use in Cell Therapies,
Gene Therapies, and Regenerative Medicine
Manufacturing: An Introduction and Best Practices
Approach on How to Prepare, Cryopreserve, and
Recover Cells, Cell Lines, and Cell-Based Tissue
Products**

PDA Standard 02-2021 Cryopreservation of Cells for Use in Cell Therapies, Gene Therapies, and Regenerative Medicine Manufacturing: An Introduction and Best Practices Approach on How to Prepare, Cryopreserve, and Recover Cells, Cell Lines, and Cell-Based Tissue Products

Authors

Brian Hawkins (Chair)
Pluristyx, Inc.

Kathy Loper (Co-Chair)
NMDP Be The Match

Alireza Abazari
Pluristyx, Inc.

Brenda Alder
Northside Hospital Cell Therapy Program

Judith A. Arcidiacono
U.S. Food and Drug Administration (FDA/CBER)

Rabia Ballica
U.S. Food and Drug Administration
Center for Biologics Evaluation and Research (FDA/CBER)

Stacey Brower
Cook MyoSite, Inc.

John T. Elliott
National Institute of Standards and Technology (NIST)

Bassem Gayed
Celgene

Choon Wee Goh
Roche Singapore Technical Operations Pte. Ltd.

Dawn Henke
The Standards Coordinating Body for Regenerative Medicine (SCB)

Pennie E. Hylton
U.S. Department of Health and Human Services (HHS/ASPR/BARDA)

Peter Kilbride
Cytiva

Seth Kreger
Cook MyoSite, Inc.

Sanjibita Mishra
Kite Pharma

Shannon Pasley
Akron Biotech

Darius Pillsbury
ValSource

Samuel D. Stevens
Fred Hutchinson Cancer Research Center

Anthony Tavera
U.S. Department of Health and Human Services (HHS/ASPR/BARDA)

Melanie Tellers
Organon

Wen Bo Wang*
Fate Therapeutics, Inc.

Claudia Zylberberg
Akron Biotech

*In Memoriam of Wen Bo Wang, a contributor and a great member of this scientific community who unfortunately passed away before this standard was published.

About PDA Standards

The goal of a Parenteral Drug Association (PDA) - American National Standard (ANS) is to provide a reliable basis for people to share the same expectations about a product or service. PDA ANS documents are developed under the American National Standards Institute (ANSI). These standards are global consensus documents, prepared by consensus-driven work groups (listed above) composed of content experts working in the pharmaceutical/biopharmaceutical industry, regulatory authorities, academia, and those individuals who have a general interest in the materials, products, systems, or services being covered in the scope of the standard.

While in development, PDA ANSI Standards are subjected to a global review of PDA members, the general public, and other topic-specific experts, often including regulatory officials. Comments from the global review are then considered and responded to by the authoring work group during the preparation of the final working draft. The level of expertise of the work group and those participating in the consensus review ensure a broad perspective reflecting best thinking and practices currently available.

The final working draft is next reviewed by the PDA Advisory Board or Boards.

The Advisory Boards of PDA provide scientific and technical expertise to the PDA Board of Directors as well as day-to-day content management of scientific and technical initiatives intended for PDA publication. PDA's Advisory Boards (AB) are: Science Advisory Board (SAB), Biotechnology Advisory Board (BioAB), Regulatory Affairs and Quality Advisory Board (RAQAB), and Advanced Therapy Medicinal Products Advisory Board (ATMP AB).

Following this stage of review, the PDA Board of Directors conducts the final review and determines whether to submit the committee draft to the ANSI Executive Standards Council (ExSC) to accept and publish or not publish the document as an official ANSI American National Standard (ANS). Approval of a PDA standard as an American National Standard (ANS) means that the standard meets [ANSI's Essential Requirements](#), the U.S. federal government's definition of a Voluntary Consensus Standard per [OMB A119](#), and the [World Trade Organization's \(WTO\) Technical Barriers to Trade \(TBT\) Code of Good Practice \(CGP\)](#) criteria for openness, transparency, impartiality and consensus, relevance, and effectiveness.

While PDA goes to great lengths to ensure that each ANSI Standard is of the highest quality, all readers are encouraged to contact PDA about any scientific, technical, or regulatory inaccuracies, discrepancies, or mistakes that might be found in any of the documents. Readers can email PDA at: standards@pda.org.

Sanctioning Advisory Board: BioAB

Chair: Morten Munk	Co-Chair: Andrew Chang	Past-Chair: Michael DeFelippis
Ed Balkovic	Michael Blackton	Jose Caraballo
Dayue Chen	Maxwell De Long	John Geigert
Brian Hawkins	Olivia Henderson	Christopher Hwang
Margit Jeschke	Stephan Krause	Peter Makowenskyj
Nicola Rose	Sebastian Teitz	Stephanie Verbrugge
Tami Wu	Earl Zablackis	

PDA Officers and Directors

Officers:

Chair: Jette Christensen, Novo Nordisk

Chair-Elect: Susan Schniepp, RCA

Treasurer: Melissa Seymour, Biogen, Inc.

Secretary: Emma Ramnarine, Genentech/Roche

Immediate Past-Chair: Rebecca Devine, Consultant

President: Richard Johnson

Directors:

Barbara Allen, Eli Lilly and Company

Michael Blackton, Adaptimmune

Bettine Boltres, West Pharmaceutical Services

Tia Bush, Amgen

Javier Camposano, Celltrion

Ghada Haddad, Merck & Co.

Joyce Hansen, Johnson & Johnson

Stephan Krause, AstraZeneca Biologics

Mary Oates, Emergent Bioscience

Mathias Romacker, Pfizer (ret.)

Anil Sawant, Merck & Co.

Osamu Shirokizawa, Lifescientia

ANSI/PDA Standard 02-2021 Cryopreservation of Cells for Use in Cell Therapies, Gene Therapies, and Regenerative Medicine Manufacturing: An Introduction and Best Practices Approach on How to Prepare, Cryopreserve, and Recover Cells, Cell Lines, and Cell-Based Tissue Products

©2021 Parenteral Drug Association

All rights reserved.



Contents

1	Introduction	3
2	Scope	3
3	Normative references	3
4	Terms and definitions	4
5	Acronyms	5
6	Critical Quality Attributes of the Cell-based Product	6
7	Cryopreservation Process Steps and Critical Process Parameters	6
7.1	Material qualification	7
7.2	Process parameters	8
8	Cell Characterization and Testing	9
8.1	Identity/Appearance	10
8.2	Purity	10
8.3	Viability	10
8.3.1	Viability testing	10
8.3.2	Viability timepoint considerations	10
8.4	Biological function	11
8.5	Sterility assurance and testing	11
8.6	Mycoplasma	11
8.7	Viral and other adventitious agent testing	11
8.8	Stability	11
9	Formulation Development	11
9.1	Cryopreservation medium	11
9.2	Cryoprotectant agent	12
9.2.1	Qualification for cryoprotectant agents	12
9.2.2	Cryoprotective agent exposure	12
10	Cryogenic Container Closure Systems	12
10.1	Cell package selection, qualification, quality control, and integrity testing	12
10.1.1	Container integrity/secondary container considerations	13
11	Cryopreservation Procedures	13
11.1	Qualification of freezing device	13
11.2	Ice nucleation	13
11.3	Transfer	14
11.4	Documentation	14
12	Cryogenic Storage and Transport	14
12.1	Cryogenic storage	14
12.2	Alert limits and action	14
12.3	In-process hold	14
12.4	Transport	15
12.5	Label integrity	15
12.6	Equipment and qualification	15
13	Thawing	15
13.1	Duration of thaw	15
13.2	Holding before freezing or after thawing process (post-thaw hold)	15
13.3	Washing	16
14	Bibliography/References	17



Bethesda Tower
4350 East West Highway
Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
E-mail: info@pda.org
Web site: www.pda.org